Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis
Thierry Façon, Shaji Kumar, Robert Z. Orlowski, Nizar J. Bahlis et autres
0 citationsLeukemia
Xavier Leleu
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
1196Publications signalées
44347Citations signalées
4Affiliations récentes
Institutions déclarées
Domaines associés
Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia ResearchProtein Degradation and InhibitorsCancer Treatment and PharmacologyPeptidase Inhibition and Analysis
Publications récentes
Blood-based MALDI-TOF mass spectrometry versus bone marrow MRD for monitoring multiple myeloma: CASSIOPEIA study results
Thomas Dejoie, Neila Rebouh, Jill Corre, Soraya Wuillème et autres
0 citationsBlood
Clinical outcomes of newly diagnosed myeloma patients with SLIM criteria : a subgroup analysis of the CASSIOPEIA study
Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Mammoun Dib et autres
0 citationsLeukemia
Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial
Aurore Perrot, Cyrille Touzeau, Stéphane Minvielle, Cyrille Hulin et autres
0 citationsBlood Cancer Journal
P36 | EFFECTIVENESS OF BRIDGING THERAPY CORRESPONDS TO IMPROVED OUTCOMES AFTER CILTACABTAGENE AUTOLEUCEL: PHASE 3 CARTITUDE-4 STUDY OF PATIENTS WITH RELAPSED, LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA
E Zamagni, B. Dhakal, S. Iida, M Hasib Sidiqi et autres
0 citationsHaematologica
P12 | SUBCUTANEOUS DARATUMUMAB (DARA) + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE WITH DARA + LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVE
Pieter Sonneveld, Ph. Moreau, H Einsele, H Quach et autres
0 citationsHaematologica
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial
Hermann Einsele, J. San‐Miguel, Binod Dhakal, Cyrille Touzeau et autres
41 citationsThe Lancet Oncology
Apixaban pharmacokinetics in newly diagnosed multiple myeloma patients treated in the benefit and isasocut clinical trials: The apixabor/mibapix study
Émilie Chalayer, Élisabeth Daguenet, Arthur Bobin, Thomas Fatrara et autres
1 citationBlood
Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma
Binod Dhakal, Shinsuke Iida, M Hasib Sidiqi, Elena Zamagni et autres
10 citationsBlood
Favorable impact of patient's selection on outcome of Relapsed/Refractory multiple myeloma treated with idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy; Experience in french patients (Super-FENIX): An IFM study from the descar-T registry
Bertrand Arnulf, Jérôme Lambert, Lionel Karlin, Cyrille Touzeau et autres
1 citationBlood
The resistec study: Dissecting immune correlates of resistance and response to teclistamab in real-world multiple myeloma
Liliana E. Lucca, Ossama Kohil, Marine Cuisinier, Marie-Véronique Joubert et autres
0 citationsBlood
Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome
Jin Lu, Albert Oriol, Alejandro Berkovits, Andrew Spencer et autres
0 citationsBlood
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.